Dong Kim, MD, discusses the evolving decision-making process for selecting a frontline chemotherapy regimen in pancreatic cancer.
Dong Kim, MD
Advertisement
Dong Kim, MD, is an oncologist and hematologist at Maryland Oncology Hematology.
Articles by Dong Kim, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Sofi-Cel Earns FDA Breakthrough Therapy Designation in Heavily Pretreated R/R T-ALL and T-LBL
2
HS-20093 Shows Promising Activity in Relapsed/Refractory Sarcoma
3
Emerging Data With Oral SERDs Reframe Frontline and Post–CDK4/6 Decisions in ER+ Breast Cancer
4
Zavabresib Nets FDA Orphan Drug Designation for Myelofibrosis
5